- Home
- DVA vs EXEL Comparison
DVA vs EXEL Comparison
Compare DVA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVA | EXEL |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.0B |
| IPO Year | 2003 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DVA | EXEL |
|---|---|---|
| Price | $180.74 | $51.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $156.75 | $46.50 |
| AVG Volume (30 Days) | 958.3K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | ★ 6.86 | 1.60 |
| Revenue | ★ $13,643,069,000.00 | $452,477,000.00 |
| Revenue This Year | $3.85 | $13.61 |
| Revenue Next Year | $3.07 | $13.13 |
| P/E Ratio | ★ $26.11 | $31.63 |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $101.00 | $33.76 |
| 52 Week High | $247.49 | $57.57 |
Technical Indicators
Market Signals| Indicator | DVA | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 27.40 | 40.73 |
| Support Level | $176.59 | $50.80 |
| Resistance Level | $202.63 | $52.84 |
| Average True Range (ATR) | 8.14 | 1.95 |
| MACD | -5.52 | -0.61 |
| Stochastic Oscillator | 6.65 | 15.63 |
Price Performance
Historical ComparisonAbout DVA DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.